Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma.
Sudoscan
bortezomib
multiple myeloma
nerve conduction study
peripheral neuropathy
sudomotor function
Journal
Archives of medical science : AMS
ISSN: 1734-1922
Titre abrégé: Arch Med Sci
Pays: Poland
ID NLM: 101258257
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
07
2019
accepted:
16
11
2019
entrez:
20
5
2022
pubmed:
11
1
2021
medline:
11
1
2021
Statut:
epublish
Résumé
In the past few years, treatment of multiple myeloma has undergone a deep change for the employment of novel treatment comprising proteasome inhibitors. Bortezomib is a first-line drug in therapy of multiple myeloma. The onset of peripheral neuropathy is a dose-limiting collateral effect of the drug. This neuropathy is a distal symmetric neuropathy that affects both large and small fibers. Nerve conduction study (NCS) can be used for the diagnosis of bortezomib neuropathy, but this technique demonstrates alterations of the large nerve fibers. Sudoscan is a novel technique utilized to offer an evaluation of sudomotor function. The main objective of this study was to compare the sensitivity and diagnostic specificity of Sudoscan with respect to the nerve conduction study after bortezomib treatment. A total of 18 multiple myeloma patients were studied, 10 (55.5%) men and 8 (44.5%) women. Patients were analyzed at baseline and after 6 months of treatment with bortezomib. Subjects were submitted to nerve conduction study and electrochemical skin conductance evaluation with the Sudoscan device. Patients were also submitted to a clinical measure of pain and neuropathy. At baseline NCS showed that only the mean sural SAP amplitude was below the 2SD lower limit of normal in 3 (16.7%) patients, while at same time we found an alteration of Sudoscan profiles in 2 (11.1%) patients. After 6 months of treatment, the NCS profiles were altered in 13 (72.2%) patients, and the Sudoscan profiles were modified in 11 (61.1%) subjects. Our results suggest that Sudoscan can be considered for the diagnosis of bortezomib-induced neuropathy. It is objective, reproducible, and surely easier than the traditional nerve conduction study. Sudoscan may be a useful help to manage the therapeutic interventions in multiple myeloma.
Identifiants
pubmed: 35591819
doi: 10.5114/aoms/114269
pii: 114269
pmc: PMC9102521
doi:
Types de publication
Journal Article
Langues
eng
Pagination
696-703Informations de copyright
Copyright: © 2021 Termedia & Banach.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Neurochem Res. 2017 Mar;42(3):925-931
pubmed: 27422265
Clin Neurophysiol. 2018 Aug;129(8):1565-1569
pubmed: 29883834
Arch Neurol. 1998 Dec;55(12):1513-20
pubmed: 9865794
Cancer. 2007 Sep 1;110(5):1042-9
pubmed: 17654660
Sci Rep. 2014 Jul 31;4:5896
pubmed: 25077633
Br J Haematol. 2009 Mar;144(6):895-903
pubmed: 19170677
Muscle Nerve. 2010 Aug;42(2):157-64
pubmed: 20658599
Int J Low Extrem Wounds. 2004 Mar;3(1):16-21
pubmed: 15866784
J Neurooncol. 2016 Apr;127(2):373-80
pubmed: 26749101
Mayo Clin Proc. 1989 Jun;64(6):617-28
pubmed: 2747292
Cancer Res. 2005 May 1;65(9):3828-36
pubmed: 15867381
Diabetes Metab Res Rev. 2011 Oct;27(7):639-53
pubmed: 21695768
Neurology. 2005 Jan 25;64(2):199-207
pubmed: 15668414
Diabetes Care. 2005 Sep;28(9):2192-200
pubmed: 16123489
Nat Genet. 2013 Oct;45(10):1221-1225
pubmed: 23955597
Arch Med Sci. 2018 Oct;14(6):1333-1339
pubmed: 30393487
Eur J Haematol. 2013 Jun;90(6):441-68
pubmed: 23506222
J Clin Nurs. 2005 Aug;14(7):798-804
pubmed: 16000093
Clin J Pain. 2018 Jan;34(1):30-36
pubmed: 28481836
Diabetes Metab. 2013 Apr;39(2):126-31
pubmed: 23159130
Clin Neurophysiol. 2018 Aug;129(8):1618-1623
pubmed: 29890373
Electromyogr Clin Neurophysiol. 2000 Jun;40(4):231-6
pubmed: 10907601
Leuk Lymphoma. 2010 Jul;51(7):1178-87
pubmed: 20497001
Eur J Haematol. 2011 Feb;86(2):93-110
pubmed: 21114539
Brain Res. 2014 Jul 29;1574:6-13
pubmed: 24949562
Annu Int Conf IEEE Eng Med Biol Soc. 2007;2007:4544-7
pubmed: 18003016
J Pain. 2011 Sep;12(9):1017-24
pubmed: 21703938
Diabetes Care. 2001 Feb;24(2):250-6
pubmed: 11213874
Front Endocrinol (Lausanne). 2015 Jun 11;6:94
pubmed: 26124748
Biophys J. 1998 Feb;74(2 Pt 1):843-56
pubmed: 9533696
Diabetes Technol Ther. 2013 Nov;15(11):948-53
pubmed: 23889506
Endocrine. 2014 Dec;47(3):690-8
pubmed: 24839196
Diabetes Metab. 2011 Dec;37(6):527-32
pubmed: 21715211
Leukemia. 2014 May;28(5):1122-8
pubmed: 24157580
Pharmacol Ther. 2018 Feb;182:176-192
pubmed: 28911826
Pain. 2014 Dec;155(12):2461-2470
pubmed: 25261162
Haematologica. 2007 Oct;92(10):1308-10
pubmed: 18024368
Neurotoxicology. 2013 Dec;39:124-31
pubmed: 24035926
J Diabetes Complications. 2014 Jul-Aug;28(4):511-6
pubmed: 24661818
J Diabetes Complications. 2015 Apr;29(3):372-7
pubmed: 25690405
Nat Commun. 2016 Jul 01;7:12050
pubmed: 27363682
Leuk Res. 2014 Jan;38(1):1-9
pubmed: 24239172
Lancet Oncol. 2010 Nov;11(11):1086-95
pubmed: 20932799
Haematologica. 2011 May;96(5):729-37
pubmed: 21228035
PLoS One. 2015 Oct 12;10(10):e0138224
pubmed: 26457582
Diabetes Metab. 2010 Dec;36(6 Pt 1):450-4
pubmed: 20739207
Inflamm Res. 2012 Oct;61(10):1063-7
pubmed: 22674324
Diabetes Metab Res Rev. 2011 Oct;27(7):665-77
pubmed: 21748841
Blood. 2013 Jan 31;121(5):858
pubmed: 23372151
Annu Rev Pharmacol Toxicol. 2006;46:189-213
pubmed: 16402903